Trium Capital LLP Aclaris Therapeutics, Inc. Transaction History
Trium Capital LLP
- $350 Million
- Q3 2024
A detailed history of Trium Capital LLP transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Trium Capital LLP holds 1,912,990 shares of ACRS stock, worth $7.63 Million. This represents 0.63% of its overall portfolio holdings.
Number of Shares
1,912,990
Previous 1,892,050
1.11%
Holding current value
$7.63 Million
Previous $2.08 Million
5.72%
% of portfolio
0.63%
Previous 0.26%
Shares
2 transactions
Others Institutions Holding ACRS
# of Institutions
84Shares Held
50.7MCall Options Held
30.6KPut Options Held
1K-
Bml Capital Management, LLC Zionsville, IN14.3MShares$56.9 Million9.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.69MShares$18.7 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.37MShares$13.5 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.01MShares$12 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.75MShares$11 Million0.11% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $266M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...